benzyl 2-(chlorocarbonyl)-7-azaspiro[3.5]nonane-7-carboxylate | 1227610-44-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl 2-(chlorocarbonyl)-7-azaspiro[3.5]nonane-7-carboxylate
• 英文别名: Benzyl 2-(chlorocarbonyl)-7-azaspiro[3.5]nonane-7-carboxylate；benzyl 2-carbonochloridoyl-7-azaspiro[3.5]nonane-7-carboxylate
• CAS: 1227610-44-7
• 化学式: C₁₇H₂₀ClNO₃
• 分子量: 321.804
• InChiKey: NXEXXUZGFNSPPL-UHFFFAOYSA-N

物化性质

• 沸点：
  446.6±45.0 °C(Predicted)
• 密度：
  1.27±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  benzyl 2-(chlorocarbonyl)-7-azaspiro[3.5]nonane-7-carboxylate 在 palladium on activated charcoal 、 氢气 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 4.25h， 生成 (4-cyclobutyl-1,4-diazepan-1-yl)(7-azaspiro[3.5]nonan-2-yl)-methanone
  参考文献：
  名称：

  Discovery of Spirofused Piperazine and Diazepane Amides as Selective Histamine-3 Antagonists with in Vivo Efficacy in a Mouse Model of Cognition

  摘要：

  A new series of potent and selective histamine-3 receptor (H3R) antagonists was identified on the basis of an azaspiro[2.5]octane carboxamide scaffold. Many scaffold modifications were largely tolerated, resulting in nanomolar-potent compounds in the H3R functional assay. Exemplar compound 6s demonstrated a selective profile against a panel of 144 secondary pharmacological receptors, with activity at only sigma 2 (62% at 10 mu M). Compound 6s demonstrated free-plasma exposures above the IC50 (similar to 50x) with a brain-to-plasma ratio of similar to 3 following intravenous dosing in mice. At three doses tested in the mouse novel object recognition model (1, 3, and 10 mg/kg s.c.), 6s demonstrated a statistically significant response compared with the control group. This series represents a new scaffold of H-3 receptor antagonists that demonstrates in vivo exposure and efficacy in an animal model of cognition.

  DOI：

  10.1021/jm4014828
• 作为产物：
  描述：

  benzyl 2-formyl-7-azaspiro[3.5]nonane-7-carboxylate 在 2,2,6,6-tetramethyl-piperidine-N-oxyl 、 sodium hypochlorite 、 草酰氯 、 碳酸氢钠 、 sodium bromide 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 6.0h， 生成 benzyl 2-(chlorocarbonyl)-7-azaspiro[3.5]nonane-7-carboxylate
  参考文献：
  名称：

  Discovery of Spirofused Piperazine and Diazepane Amides as Selective Histamine-3 Antagonists with in Vivo Efficacy in a Mouse Model of Cognition

  摘要：

  A new series of potent and selective histamine-3 receptor (H3R) antagonists was identified on the basis of an azaspiro[2.5]octane carboxamide scaffold. Many scaffold modifications were largely tolerated, resulting in nanomolar-potent compounds in the H3R functional assay. Exemplar compound 6s demonstrated a selective profile against a panel of 144 secondary pharmacological receptors, with activity at only sigma 2 (62% at 10 mu M). Compound 6s demonstrated free-plasma exposures above the IC50 (similar to 50x) with a brain-to-plasma ratio of similar to 3 following intravenous dosing in mice. At three doses tested in the mouse novel object recognition model (1, 3, and 10 mg/kg s.c.), 6s demonstrated a statistically significant response compared with the control group. This series represents a new scaffold of H-3 receptor antagonists that demonstrates in vivo exposure and efficacy in an animal model of cognition.

  DOI：

  10.1021/jm4014828

文献信息

• Spirocyclobutyl Piperidine Derivatives
  申请人：Bernstein Peter

  公开号：US20100130477A1

  公开（公告）日：2010-05-27

  Disclosed herein is at least one spirocyclobutyl piperidine derivative, at least one pharmaceutical composition comprising at least one spirocyclobutyl piperidine derivative disclosed herein, and at least one method of using at least one spirocyclobutyl piperidine derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith.

  披露至少一种螺环环丁基哌啶衍生物，至少一种包含本文披露的至少一种螺环环丁基哌啶衍生物的药物组合物，以及至少一种使用本文披露的至少一种螺环环丁基哌啶衍生物治疗至少一种组胺H3受体相关状况的方法。
• [EN] SPIROCYCLOBUTYL PIPERIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE PIROCYCLOBUTYLPIPÉRIDINE
  申请人：ASTRAZENECA AB

  公开号：WO2010062245A1

  公开（公告）日：2010-06-03

  Disclosed herein is at least one spirocyclobutyl piperidine derivative with formula I, or pharmaceutically acceptable salts of formula I, or mixtures thereof: wherein A is at least one pharmaceutical composition comprising at least one spirocyclobutyl piperidine derivative disclosed herein, and at least one method of using at least one spirocyclobutyl piperidine derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith.